This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
In response to recent data fraud findings, the China Food and Drug Administration (CFDA) has ruled that its approved generic drugs be retested. For pharmaceutical companies, investigators, and CROs there is more pressure than ever to improve drug quality and reporting— or be blacklisted.
Can you trust BE drug trial results from China, and is it advisable for pharma companies to plan their next study there?
Get answers to these and other burning questions when you download this whitepaper from Citeline. Leveraging real-time data intelligence from Trialtrove, the industry’s most comprehensive, accurate and up-to-date source of pharmaceutical clinical trials data, this paper dives deep into the history, current landscape and future of bioequivalence studies in China including:
The major players sponsoring BE trials now, and the drugs they are testing